In addition, the PI3K-Akt signaling pathway and NF-kappa B signaling pathway were enriched by the OS gene set B. Growing evidence suggested that targeting PI3K-Akt signaling pathway may represent an effective treatment to kill AML LSCs [33, 34], and NF-kappa B inhibitor LC1 also showed an inhibitory effect on primary AML cells in vitro [35]. The gene discussed is AKT1; the disease is acute myeloid leukemia.